stop_circleTerminated/Withdrawn
Endometrial hyperplasia
Bayer Identifier:
22923
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Mirena for the treatment of nonatypical endometrial hyperplasia for 6 months
Trial purpose
Researchers are looking for a better way to treat women with nonatypical endometrial hyperplasia (NAEH).
Endometrial hyperplasia is a condition where the lining of the uterus (called the endometrium) becomes too thick. Nonatypical means that the condition is not cancerous. It is often caused by hormone imbalances in women. Symptoms can include abnormal vaginal bleeding or irregular periods. If this condition is not treated, then it may lead to cancer.
Currently, there are no approved treatments for NAEH and that is why there is still an unmet medical need.
The study treatment, Mirena (also known as BAY 865028), is already available as a type of birth control device. It is inserted into the uterus where it gradually releases progesterone.
In this study, researchers want to find out if Mirena works for women with NAEH. They believe it can help by keeping hormone levels balanced in the body.
The main purpose of this study is to show that uterine lining goes back to completely normal lining after treatment with Mirena and that its use is safe in this population.
For this, the researchers will compare the number of participants with benign endometrium after 6 months of treatment with Mirena or oral MPA.
The study participants will be randomly assigned into one of two treatment groups. The randomization will be done 2:1 ratio, meaning that for every two participants assigned to Mirena, one will be assigned to oral medroxyprogesterone acetate (MPA). Based on their group, participants will receive Mirena, which is inserted into the uterus at the start of the study, or they will take progestins once daily by mouth for 6 months.
Each participant will be in the study for around 10 months with up to 5 visits to the study clinic/site.
Participants will visit the study clinic:
- once before the treatment starts
- 3 times with a gap of 3 months between the visits during the treatment
- then 1 more time after the treatment ends
During the study, the doctors and their study team will:
- check participant's health by performing tests such as blood and urine tests
- perform vaginal ultrasound and hysteroscopy. Hysteroscopy is a minor surgical procedure where a thin camera will be inserted into the womb to check for any abnormality. Sampling of the endometrial lining (cells in the womb) will be done with a thin tube at the same time.
- take samples of womb (endometrial) lining
- ask the participants questions about how they are feeling and what adverse events they are having
An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatment.
Endometrial hyperplasia is a condition where the lining of the uterus (called the endometrium) becomes too thick. Nonatypical means that the condition is not cancerous. It is often caused by hormone imbalances in women. Symptoms can include abnormal vaginal bleeding or irregular periods. If this condition is not treated, then it may lead to cancer.
Currently, there are no approved treatments for NAEH and that is why there is still an unmet medical need.
The study treatment, Mirena (also known as BAY 865028), is already available as a type of birth control device. It is inserted into the uterus where it gradually releases progesterone.
In this study, researchers want to find out if Mirena works for women with NAEH. They believe it can help by keeping hormone levels balanced in the body.
The main purpose of this study is to show that uterine lining goes back to completely normal lining after treatment with Mirena and that its use is safe in this population.
For this, the researchers will compare the number of participants with benign endometrium after 6 months of treatment with Mirena or oral MPA.
The study participants will be randomly assigned into one of two treatment groups. The randomization will be done 2:1 ratio, meaning that for every two participants assigned to Mirena, one will be assigned to oral medroxyprogesterone acetate (MPA). Based on their group, participants will receive Mirena, which is inserted into the uterus at the start of the study, or they will take progestins once daily by mouth for 6 months.
Each participant will be in the study for around 10 months with up to 5 visits to the study clinic/site.
Participants will visit the study clinic:
- once before the treatment starts
- 3 times with a gap of 3 months between the visits during the treatment
- then 1 more time after the treatment ends
During the study, the doctors and their study team will:
- check participant's health by performing tests such as blood and urine tests
- perform vaginal ultrasound and hysteroscopy. Hysteroscopy is a minor surgical procedure where a thin camera will be inserted into the womb to check for any abnormality. Sampling of the endometrial lining (cells in the womb) will be done with a thin tube at the same time.
- take samples of womb (endometrial) lining
- ask the participants questions about how they are feeling and what adverse events they are having
An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatment.
Key Participants Requirements
Sex
FemaleAge
18 - N/A (No Limit)Trial summary
Enrollment Goal
0Trial Dates
November 2025 - June 2026Phase
Phase IIICould I Receive a placebo
NoProducts
Levonorgestrel, BAY 865028Accepts Healthy Volunteer
NoWhere to participate
| Status | Institution | Location |
|---|---|---|
Completed | Cornerstone Clinic for Women – Aldersgate | Little Rock, 72205, United States |
Active, not recruiting | Lyndhurst Clinical Research | Winston Salem, 27103, United States |
Active, not recruiting | AIH Research- Broadway | Pearland, 77584, United States |
Active, not recruiting | Discovery Clinical Trials - Dallas | Dallas, 75230, United States |
Active, not recruiting | Southern Clinical Research Associates | Metairie, 70001, United States |
Active, not recruiting | ClinOhio Research Services, LLC. | Columbus, OH | Columbus, 43213, United States |
Active, not recruiting | Unified Women's Clinical Research - Centre OB/GYN | Raleigh, 27607, United States |
Active, not recruiting | Biopharma Informatic - West Houston | Houston, 77043, United States |
Active, not recruiting | Bosque Women's Care | Albuquerque, NM | Albuquerque, 87109, United States |
Active, not recruiting | Omni Fertility and Laser Institute | Shreveport, 71118, United States |
Active, not recruiting | OB/GYN Associates of Erie | Erie, 16507, United States |
Active, not recruiting | Revive Research Institute - Michigan - Women's Health | Dearborn Heights, 48127, United States |
Active, not recruiting | Chattanooga Medical Research, LLC. | Chattanooga, TN | Chattanooga, 37412, United States |
Active, not recruiting | Office of Dr. Cindy Basinski, LLC | Evansville, 47715, United States |
Active, not recruiting | Sweet Hope Research Specialty, Inc. - Hialeah | Hialeah, 33016, United States |
Active, not recruiting | Paramount Research Solutions | College Park Location | Atlanta, 30327, United States |
Active, not recruiting | Emerald Coast Clinical Research | Panama City, 32405, United States |
Active, not recruiting | Alliance Clinical West Hills | West Hills, 91307, United States |
Active, not recruiting | Velocity Clinical Research - Lafayette | Lafayette, 70508, United States |
Active, not recruiting | Velocity Clinical Research - Phoenix | Phoenix, 85006, United States |
Active, not recruiting | Entrust Clinical Research | Palmetto Bay, 33176, United States |
Active, not recruiting | New Age Medical Research Corp. | Miami, 33186, United States |
Active, not recruiting | The Ottawa Hospital, Riverside Campus - Department of Obstetrics, Gynecology and Newborn Care | Ottawa, K1H 7W9, Canada |
Not Yet Recruiting | Mount Sinai Hospital Toronto | Gynecology | Toronto, M5G 1Z5, Canada |
Active, not recruiting | Centres Investigation Clinique Mauricie | Trois-Rivieres, G8T 7A1, Canada |
Active, not recruiting | Peking Union Medical College Hospital CAMS | Beijing, 100730, China |
Active, not recruiting | Chongqing Maternal and Child Health Care Hospital | Chongqing, 401147, China |
Active, not recruiting | Jiangxi Maternal and Child Health Hospital | Nanchang, 330006, China |
Active, not recruiting | Nanjing Medical University (NMU) - The Second Affiliated Hospital | Nanjing, 210011, China |
Active, not recruiting | Women and Children's Hospital, Qingdao University - Gynecology department | Qingdao, 266034, China |
Active, not recruiting | Chengdu Women & Children's Central Hospital | Chengdu, 610091, China |
Active, not recruiting | Xiamen Maternity and Child Health Care Hospital - Gynecology Department | Xiamen, 361003, China |
Active, not recruiting | Nanjing Maternity and Child Health Care Hospital | Nanjing, 210004, China |
Active, not recruiting | Tangshan Maternal and Child Health Care Hospital | Tangshan, 063014, China |
Active, not recruiting | China-Japan Friendship Hospital | Beijing, 100029, China |
Active, not recruiting | Shaanxi Provincial People's Hospital | Xi'an, 710068, China |
Active, not recruiting | Peking University Shenzhen Hospital | Shenzhen, 518036, China |
Active, not recruiting | The Third Affiliated Hospital of Southern Medical University - Gynecology Department | Guangzhou, 510630, China |
Primary Outcome
- Proportion of participants with Complete Resolution (CR) of NAEHComplete Resolution will be evaluated as benign endometrium.date_rangeTime Frame:At 6 months
Secondary Outcome
- Recurrence of NAEH after CRRecurrence of NAEH on 3 months treatment free after CR at 6 monthsdate_rangeTime Frame:At 3 months follow up after 6 months treatment
- Progression after CREndometrial hyperplasia with atypia or endometrial cancer after 3 months treatment free follow up after CR at 6 monthsdate_rangeTime Frame:At 3 months follow up after 6 months treatment
- Proportion of participants having hysterectomydate_rangeTime Frame:During treatment and 3 months follow up
- Diagnosis of "benign endometrium"date_rangeTime Frame:At 6 months of treatment followed by 3 month treatment-free follow up
- Number of participants with adverse eventsAll AEs will be coded using the latest version prior to database lock of the Medical Dictionary for Regulatory Activitiesdate_rangeTime Frame:From the signing of the informed consent form (ICF) up to 3 months after the last dose of study intervention
Trial design
Trial Type
InterventionalIntervention Type
Combination ProductTrial Purpose
TreatmentAllocation
RandomizedBlinding
Open LabelAssignment
ParallelTrial Arms
2